Abstract
Introduction: At present, vaccines form the only mode of prophylaxis against COVID-19. The time needed to achieve mass global vaccination and the emergence of new variants warrants continued research into other COVID-19 prevention strategies. The severity of COVID-19 infection is thought to be associated with the initial viral load, and for infection to occur, viruses including SARS-CoV-2 must first penetrate the respiratory mucus and attach to the host cell surface receptors. Carrageenan, a sulphated polysaccharide extracted from red edible seaweed, has shown efficacy against a wide range of viruses in clinical trials through the prevention of viral entry into respiratory host cells. Carrageenan has also demonstrated in vitro activity against SARS-CoV-2.
Methods and analysis: A single-centre, randomised, double-blinded, placebo-controlled phase III trial was designed. Participants randomised in a 1:1 allocation to either the treatment arm, verum Coldamaris plus (1.2 mg iota-carrageenan (Carragelose®), 0.4 mg kappa-carrageenan, 0.5% sodium chloride and purified water), or placebo arm, Coldamaris sine (0.5% sodium chloride) spray applied daily to their nose and throat for 8 weeks, while completing a daily symptom tracker questionnaire for a total of 10 weeks.
Primary outcome: Acquisition of COVID-19 infection as confirmed by a positive PCR swab taken at symptom onset or seroconversion during the study. Secondary outcomes include symptom type, severity and duration, subsequent familial/household COVID-19 infection and infection with non-COVID-19 upper respiratory tract infections. A within-trial economic evaluation will be undertaken, with effects expressed as quality-adjusted life years.
Discussion: This is a single-centre, phase III, double-blind, randomised placebo-controlled clinical trial to assess whether carrageenan nasal and throat spray reduces the risk of development and severity of COVID-19. If proven effective, the self-administered prophylactic spray would have wider utility for key workers and the general population.
Trial registration: NCT04590365 ; ClinicalTrials.gov NCT04590365 . Registered on 19 October 2020.
Keywords: COVID-19.
【저자키워드】 COVID-19., 【초록키워드】 COVID-19, SARS-CoV-2, Efficacy, Vaccine, vaccination, clinical trial, Trial, randomised, severity, variant, Infection, risk, nasal, Symptom, outcome, Prophylactic, viral entry, Sodium chloride, Prophylaxis, infections, Seroconversion, COVID-19 infection, severity of COVID-19, Research, carrageenan, Placebo, receptors, iota-carrageenan, kappa-carrageenan, General population, Swab, polysaccharide, utility, upper respiratory tract, questionnaire, placebo-controlled, in vitro activity, nose and throat, double-blind, host cells, symptom onset, Non-COVID-19, double-blinded, placebo-controlled clinical trial, participant, treatment arm, positive PCR, Effect, effective, secondary, host cell surface, initial viral load, thought, shown, virus, include, subsequent, applied, occur, expressed, demonstrated, reduce, purified, 1:1, penetrate, 【제목키워드】 COVID-19, Efficacy, Study protocol, randomised, nasal, placebo-controlled trial, double-blind,